-
Nimotuzumab on ASCO 2022
https://www.oncoscience.de/en/nimotuzumab-on-asco-2022/
Once again, Nimotuzumab’s efficacy and safety in several cancer types were discussed and analyzed thorou...
-
Webinar – The Role of Nimotuzumab in the Treatment of Head and Neck and Nasopharyngeal Cancer
https://www.oncoscience.de/en/webinar-the-role-of-nimotuzumab-in-the-treatment-of-head-and-neck-and-nasopharyngeal-cancer/
This webinar was conducted on May 28th, 2022 discussing the role of Nimotuzumab in the treatment of locall...
-
Specific Pharma A/S and Oncoscience GmbH launch a Named Patient Program for the treatment of cancer with nimotuzumab.
https://www.oncoscience.de/en/specific-pharma-a-s-and-oncoscience-gmbh-launch-a-named-patient-program-for-the-treatment-of-cancer-with-nimotuzumab/
Specific Pharma announced today that it has entered into a supply and distribution collaboration with German based Onc...
-
Children with diffuse intrinsic pons glioma (DIPG) benefit from nimotuzumab
https://www.oncoscience.de/en/children-with-diffuse-intrinsic-pons-glioma-dipg-benefit-from-nimotuzumab/
The results of an international clinical trial were published in March 2019. Forty-two children aged 3 to 20 years suffe...
-
Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher® (Nimotuzumab) in the U.K. and Ireland
https://www.oncoscience.de/en/mawdsleys-and-oncoscience-launch-a-named-patient-program-for-cimaher-nimotuzumab-in-the-u-k-and-ireland/
Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingd...
-
Publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine.
https://www.oncoscience.de/en/publication-shows-benefit-in-patients-with-locally-advanced-or-metastatic-pancreatic-cancer-treated-with-nimotuzumab-in-combination-with-gemcitabine/
New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab...
-
legal form changed
https://www.oncoscience.de/en/legal-form-changed/
We are now Oncoscience GmbH. Managing directors are Dr. Dirk Reuter, Dr. Budhi Simon and Robert Ellerson....
-
MOVE
https://www.oncoscience.de/en/move/
WE'RE MOVING Our new address and phone numbers (effective may 3rd 2016): Osterbrooksweg 59 22869 Schenefeld Phone: +4...
-
Oncoscience AG attends the Nimotuzumab Global Scientific Meeting, 7th-10th April 2016 in Varadero/ Cuba
https://www.oncoscience.de/en/oncoscience-ag-attends-the-nimotuzumab-global-scientific-meeting-7th-10th-april-2016-in-varadero-cuba/
At this global clinical development meeting, more than 150 researches from over 20 countries discuss the latest results ...
-
Search
https://www.oncoscience.de/en/search/
...
